Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Takeda Pharmaceutical Co. (TAK) has completed a Phase 1b study of its antibody therapy TAK-079, also known as mezagitamab, in newly diagnosed multiple myeloma patients who are not expected to receive a stem cell transplant. The trial aimed to find a suitable dose for later-stage studies and to review long-term safety, marking an early step in expanding Takeda’s blood cancer portfolio.
The study tested subcutaneous TAK-079 added to standard myeloma drug combinations. These included lenalidomide plus dexamethasone, known as LenDex, and bortezomib with lenalidomide and dexamethasone, often called VRd. The goal was to see if adding TAK-079 could safely improve outcomes without causing too many side effects.
This was an interventional, non-randomized study, meaning all participants received an active treatment and were not assigned by chance to different groups. It used parallel groups with no placebo and was open label, so both doctors and patients knew which drugs were given, with the main aim being treatment rather than prevention or diagnosis.
The trial was first submitted in June 2019, reflecting Takeda’s push into new myeloma options. The study is now listed as completed, and the most recent update on ClinicalTrials.gov was posted on Apr. 8, 2026, signaling that Takeda has refreshed the record and may be preparing for data disclosure or follow-on studies.
For investors, the completion and recent update of this early-stage TAK-079 trial suggest continued commitment to myeloma and to antibody-based platforms at Takeda. While Phase 1b results rarely move the stock on their own, they can support long-term growth expectations, especially as Takeda competes with players like Bristol Myers, Johnson & Johnson, and Amgen in the crowded multiple myeloma market.
The TAK-079 multiple myeloma program remains active at the data and planning level, and the study record has been recently updated, with further detail and status available on the ClinicalTrials.gov portal under NCT03984097.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.